Trending...
- Z-CoiL Footwear, Albuquerque's Original Spring Shoe, Steps Into ABC's Shark Tank Season Premiere
- Invisible Wounds Foundation Launches Brain Health Collaborative to Combat Traumatic Brain Injury in Service Members and Prevent Military Suicides
- NIUFO Examines European MiCA Regulation's Impact on Digital Asset Trading Markets
JUPITER, Fla. - illiNews -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the first physicians in the country to administer the newly FDA-approved drug Kisunla to patients. This groundbreaking development marks a significant milestone in neurological care, offering new hope to patients battling a range of neurological conditions.
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on illi News
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on illi News
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Kisunla, by Eli Lilly represents a promising advancement in neurology, specifically targeting Alzheimer's disease and dementia. Kisunla is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
Dr. Jeff Gelblum, Neurologist in Aventura, Florida, has significant experience using anti-amyloid infusion therapy for his patients with mild cognitive impairment and mild Alzheimer's disease. He has many patients taking Leqembi with which was FDA approved in July 2023.
He is also looking forward to using Kisunla in his patients for the same conditions and differentiates the two products, accordingly: "The two drugs target the same endpoint, reduction of brain amyloid plaque which is a marker of Alzheimer's disease. Leqembi is given twice a month for a full 18 months. Kisunla is once a month and may be able to be stopped as soon as six months, based upon clearance of amyloid plaque on a follow up brain PET scan. Leqembi has a lower incidence of side effects of brain swelling and bleeding."
More on illi News
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025
- Prostate Cancer Survivor's Podcast Grows Audience And Builds Marketing Muscle
- CCHR, a Mental Health Watchdog Organization, Hosts Weekly Events Educating Citizens on Important Mental Health Issues
- Goat Skin Chicago Partners With Inkdnylon Custom Apparel to Strengthen Brand Growth
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience
Gelblum notes, "that a patient who is unable to go for twice monthly infusions and eager to possibly conclude treatment in as soon as six months, who can also assume the greater safety risk, would be a good candidate for the new treatment."
Dr. Jennifer Buczyner, Neurologist in Jupiter, Florida said, "The approval of Kisunla offers another opportunity for patients with mild cognitive impairment or mild dementia and brings those with mild cognitive impairment to early medical attention. In studies, Kisunla slowed cognitive and functional decline by up to 35 percent compared to placebo at 18 months and reduced patients' risk of progressing to the next clinical stage of disease by up to 39 percent. We at First Choice Neurology are very excited to offer anti-amyloid therapies to our South Florida communities."
The introduction of Kisunla underscores First Choice Neurology's commitment to pioneering treatments that transform the landscape of neurological care. As the first physicians in the United States to administer Kisunla, Dr. Gelblum and Dr. Buczyner exemplify the group's leadership in bringing cutting-edge therapies to patients.
More on illi News
- New Slotozilla Project Explores What Happens When the World Goes Silent
- The Two Faces of Charles D. Braun: How the Novel, Posthumously Yours, Came to Life
- JB Dondolo Global Call for Clean Water with Grammy-submitted single "We Are the Leaders"
- NEIU College of Business and Technology's bachelor's in Computer Science has been accredited by the Computing Accreditation Commission of ABET
- Riviera Marketing & MAZ6R CLAN: Tribute to the Twin Tower Tragedy!
About First Choice Neurology
First Choice Neurology is the largest neurology group in the United States with over 60 Care Centers in multiple Florida counties and services at more than 45 major hospitals. The group provides comprehensive neurological care for patients with a wide range of conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, Parkinson's disease, sleep disorders, strokes, traumatic brain injuries, and more. With a commitment to innovation and patient-centered care, First Choice Neurology continues to lead advancements in neurological treatments nationwide.
For more information about Kisunla and First Choice Neurology, visit fcneurology.com
Source: First Choice Neurology
0 Comments
Latest on illi News
- Author Charlene Wexler Earns Global Book Award for We Won't Go Back
- Chicago: Mayor Brandon Johnson Welcomes New Residents At Thrive Englewood
- HCSC Expands National Footprint for Medicare Advantage Products to 30 States
- Chicago-born 21-year-old Vidagua Founder Sells 100,000 Bottles Of Aguas Frescas In First Year
- September Career Reset - How Job Seekers Are Using WIOA to Pivot Before Year-End
- Fall Prep for Your Pond - Why September is the Best Month to Get Ready for Winter
- DivX Unveils New Educational Blog Series to Simplify MKV to MP4 Video Conversion
- CCHR: For Prevention, Families Deserve Truth From NIH Study on Psychiatric Drugs
- Sheets.Market Brings Professional Financial Model Templates to Entrepreneurs and Startups
- Webinar Announcement: Investing in the European Defense Sector—How the New Era of Uncertainty Is Redefining Investment Strategies
- AEVIGRA (AEIA) Analysis Reveals $350 Billion Counterfeit Market Driving Luxury Sector Toward Blockchain Authentication
- Brazil 021 Chicago Launches Kids' Jiu-Jitsu Program to Combat Bullying and Build Confidence
- Episode Highlight: Turning Tragedy into Purpose with Barry Adkins
- Nova Collective & Fairplay Merge to Redefine Bold, Human Learning
- AstroHermetic Launches Metaphysical Consulting to Help Organizations Unlock Hidden Insights
- Her Magic Mushroom Memoir Launches as a Binge-Worthy Novel-to-Podcast Experience
- Century Fasteners de Mexico Hires Saúl Pedraza Gómez as Regional Sales Manager in Mexico
- Georgia Misses the Mark Again on Sports Betting, While Offshore Sites Cash In
- $40 Price Target for $NRXP in H. C. Wainright Analyst Report on Leader in $3 Billion Suicidal Depression Market with Superior NRX 100 Drug Therapy
- Avoiding Foreclosure Without Bankruptcy — How 4Closure Rescue LLC Gives Families a Fresh Start